Analysis of the cellular viability and migratory capacity of triple-negative breast cancer cells stimulated with doxorubicin used during neoadjuvant chemotherapy (#1479)

Authors

Vallejos Paredes, María Fernanda

Buitron Mercado, Melissa Francesca

Carpio-Carpio, Jose Miguel

Ita Balta, Yuma Aracely

Riera Perez, Angeline Caprice

Villanueva-Salas, José Antonio

Choquenaira-Quispe, Celia

Abstract

Breast cancer remains a major public health problem, especially the triple-negative molecular subtype, due to its limited response to chemotherapy. Therefore, the objective of this study was to evaluate the cellular viability and migratory capacity of triple-negative breast cancer cells treated with doxorubicin, a drug used in neoadjuvant chemotherapy. For this purpose, the MDA-MB-231 cell line was used, cultured in DMEM medium supplemented with 10% fetal bovine serum and 1% antibiotic. Response to treatment was evaluated using MTT, clonogenic, and wound healing assays. The results showed an IC₅₀ value of 0.3 µM for doxorubicin in the MDA-MB-231 cell line. It was also observed that, despite treatment, the cells retained partial migratory capacity. Taken together, these findings indicate that doxorubicin reduces cell viability but does not completely inhibit the migration of MDA-MB-231 cells, which could contribute to doxorubicin favoring the survival of this triple-negative molecular phenotype.